At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 254 enrolled
Drug / intervention
NGM282 +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Randomized, Double-blind, Placebo-controlled Study With Additional Open-label, Single-blind and Placebo-controlled Cohorts to Assess the Safety, Tolerability, and Efficacy of NGM282 in Patients With Nonalcoholic Steatohepatitis
In Brief
A Phase 2 clinical trial evaluating NGM282 and Placebo for Nonalcoholic Steatohepatitis (NASH). Completed, enrolled 254 participants across 22 sites in 3 countries.
Detailed Summary
The purpose of this study is to determine the safety, tolerability, and efficacy of NGM282 in patients with nonalcoholic steatohepatitis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNonalcoholic Steatohepatitis (NASH)
CountriesAustralia, Puerto Rico, United States
CollaboratorsNGM Biopharmaceuticals Australia Pty Ltd
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedMay 2015
Enrollment StartJul 2015
Primary CompletionDec 2019
Study CompletionJan 2020
TodayJul 2026
First PostedMay 13, 2015
Enrollment StartJul 31, 2015
Primary CompletionDec 6, 2019
Study CompletionJan 17, 2020
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 11.1 years ago
Interventions
NGM282biological
Placeboother